ASND Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.…
Industry Peers
BiotechnologyKey Statistics
About Ascendis Pharma (NASDAQ: ASND)
›
Ascendis Pharma (NASDAQ: ASND) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,189 employees.
The shares were at 252.73 USD on 20 November 2026, up 31.9% over 52 weeks. Its 52-week range is 186.05 USD to 278.56 USD: the price is 9.3% below the high and 35.8% above the low.
At a market capitalisation of 16.58B USD, it trades at 17.6 times trailing earnings and 20.9 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 34.3, a discount of 49% for ASND.
Ascendis Pharma reports return on equity of 140.1%, an operating margin of 30.9% and revenue up 73.0% year over year.
It holds more cash than debt, a net cash position of 516.56M EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 21 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 314.90 USD is 24.6% above the current price.